Approval Status
Approved June 1998

Treatment for
respiratory syncytial virus (RSV)


Synagis has been approved for the prevention of serious lower respiratory tract disease in pediatric patients at high risk of RSV disease. Synagis is the first monoclonal antibody to be licensed for any infectious disease. It is injected intramuscularly in a doctor's office.

Synagis Drug Information

The Synagis drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top